IONS / Ionis-Biogen Partnered Amyotrophic Lateral Sclerosis Trial Disappoints

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q3 2023 Earnings Conference Call November 2, 2023 11:30 AM ET Company Participants Wade Walke - Senior Vice more_horizontal

Per the agreement, Ionis (IONS) will grant exclusive global rights to Roche to develop and market two novel RNA-therapeutics for Alzheimer's and Hunti more_horizontal

Ionis Pharmaceuticals (IONS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings esti more_horizontal

Ionis Pharmaceuticals said on Tuesday its experimental drug met main goal in a late-stage trial testing it as a treatment for a rare genetic disorder more_horizontal

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? more_horizontal

Ionis Pharmaceuticals is a pioneering drug developer with a focus on antisense technology. The company has successfully developed four commercially ap more_horizontal

The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended June 2023, but it may be worthw more_horizontal

Ionis Pharmaceuticals (IONS) came out with quarterly earnings of $0.60 per share, beating the Zacks Consensus Estimate of a loss of $0.94 per share. T more_horizontal